761 / 1708
Group III Orbital RMS
N Chemotherapy
Radiotherapy Local Failure
D9602
77
VA
45 Gy
14%
IRS-III
71
VA
41.4-50.4Gy
16%
IRS-IV
50
VAC/VIE/VAE
50.4-59.4 Gy
4%
In the COG study (ARST0331), 45 Gy was used for Group III
orbital RMS with the addition of cyclophosphamide to the
chemotherapy regimen.
Breneman J et al. Int J Radiat Oncol Biol Phys 2012; 83:720-6